Today: 7 February 2026
Subscribe
Browse Category

Biotech News 17 June 2025 - 13 August 2025

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

Blockbuster Breakthroughs, Setbacks & Surges: Biotech and Health News Roundup (Aug 11–12, 2025)

IO Biotech’s Phase 3 melanoma vaccine Cylembia added to Merck’s Keytruda narrowly missed statistical significance, with median progression-free survival of 19.4 months versus 11 months for Keytruda alone. Fosun Pharma’s deal with Expedition Therapeutics grants rights outside Greater China to XH-S004, a first-in-class oral DPP-1 inhibitor for chronic respiratory diseases, in a pact potentially worth up to $645 million including $120 million upfront and up to $525 million in milestones. NextRNA Therapeutics announced on August 11 it is winding down operations after cash constraints, leaving about 27 employees. FDA approved ketamine (brand name KETARx) from PharmaTher Holdings for surgical anesthesia
12 August 2025
·
Breakthrough Cures, Big Pharma Shake-Ups & Health Policy Bombshells – Biotech/Health News (Aug 7–8, 2025)

Breakthrough Cures, Big Pharma Shake-Ups & Health Policy Bombshells – Biotech/Health News (Aug 7–8, 2025)

Scientific Breakthroughs & Discoveries (Aug 7–8, 2025) Regulatory Updates (FDA and Other Agencies) Mergers, Acquisitions & Financial News Public Health & Policy Updates Sources: The information above is sourced from recent press releases, regulatory announcements, and news reports between Aug 7–8, 2025, including Scripps Research eurekalert.org eurekalert.org, EurekAlert! eurekalert.org, Boston Globe kffhealthnews.org bostonglobe.com, UC Davis Health News health.ucdavis.edu health.ucdavis.edu, U.S. FDA releases fda.gov fda.gov fda.gov fda.gov, BioSpace and Reuters coverage of industry developments biospace.com reuters.com biospace.com biospace.com reuters.com reuters.com reuters.com reuters.com reuters.com, and health policy analyses from KFF Health News reuters.com reuters.com kffhealthnews.org. Each cited item is linked to its original
8 August 2025
Top 10 Tech Trends Exploding in 2025: Generative AI, Quantum Leaps, Biotech Breakthroughs & More

Top 10 Tech Trends Exploding in 2025: Generative AI, Quantum Leaps, Biotech Breakthroughs & More

In 2025, enterprise adoption of generative AI doubled to 65% of organizations, with 92% of Fortune 500 companies leveraging OpenAI’s technology. In June 2025 IBM announced fault-tolerant quantum error-correction progress and unveiled Starling, a 200-logical-qubit machine (~10,000 physical qubits) planned to be operational by 2029. CRISPR-based therapies for blood disorders are expected to receive regulatory approval by 2025. By mid-2025, about 1 billion wearable devices are in use worldwide, including the Apple Watch Series X and Oura rings. In 2024, 67% of organizations increased investments in generative AI apps, signaling widespread adoption of AI copilots and hyperautomation. Toyota is piloting
17 June 2025
···
1 … 11 12 13

Stock Market Today

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

PLS Group share price slips into weekend as Morgan Stanley and MUFG filings land

7 February 2026
PLS Group shares closed at A$4.12 Friday, down 1.2% after a 3.7% drop Thursday. Morgan Stanley and Mitsubishi UFJ Financial Group disclosed increased voting power in the lithium miner, both citing changes dated Feb. 2. The moves came as lithium prices fell and Australian equities posted their sharpest drop in months. PLS reports interim results Feb. 19.
Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

Commonwealth Bank share price near A$159 as CBA earnings, dividend week looms after ASX rout

7 February 2026
Commonwealth Bank of Australia shares closed at A$158.91, down 0.23% Friday, as the S&P/ASX 200 fell 2.03% and nearly A$70 billion was wiped from the market. The bank reports half-year results and an interim dividend on Feb. 11, with shares going ex-dividend Feb. 18. CBA flagged a A$68 million provision linked to ASIC’s Better Banking review. The RBA raised rates to 3.85% on Feb. 3, with CBA passing on the increase from Feb. 13.
Go toTop